Jynarque patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8501730 OTSUKA Process for preparing benzazepine compounds or salts thereof
Sep, 2026

(2 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10905694 OTSUKA Pharmaceutical solid preparation comprising benzazepines and production method thereof
Apr, 2030

(6 years from now)

Jynarque is owned by Otsuka.

Jynarque contains Tolvaptan.

Jynarque has a total of 2 drug patents out of which 0 drug patents have expired.

Jynarque was authorised for market use on 23 April, 2018.

Jynarque is available in tablet;oral dosage forms.

The generics of Jynarque are possible to be released after 07 April, 2030.

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Apr 23, 2025

Drugs and Companies using TOLVAPTAN ingredient

Market Authorisation Date: 23 April, 2018

Treatment: NA


How can I launch a generic of JYNARQUE before it's drug patent expiration?
More Information on Dosage

JYNARQUE family patents

Family Patents

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic